Lavipharm S.A.

LAVI

GRS246003008

Pharmaceuticals

Market Closed - Athens S.E. Other stock markets 15:09:50 03/06/2024 BST			5-day change	1st Jan Change
0.92 ^EUR	+0.33%		-3.16%	+15.58%

02-28	Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Lavipharm S.A. entered into a new asset purchase agreement to acquire Flagyl product line for Greek market from Sanofi.	CI

Lavipharm S A : Announcement 1668/2023

March 15, 2023 at 04:40 pm

This Announcement is available only in Greek.Flash Note Financial Results 2022

Attachments

Original Link
Original Document
Permalink

Disclaimer

Lavipharm SA published this content on 15 March 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 March 2023 16:39:06 UTC.

Latest news about Lavipharm S.A.

Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Lavipharm S.A. entered into a new asset purchase agreement to acquire Flagyl product line for Greek market from Sanofi.	12-10	CI
Lavipharm S.A. signing of an asset purchase agreement to acquire Lonarid N and Lonalgal from Boehringer Ingelheim International GmbH.	11-30	CI
Lavipharm S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	11-08	CI
Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	21/09/23	CI
Lavipharm S.A.(ATSE:LAVI) added to ATHEX Composite Index	21/06/23	CI
Lavipharm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	04/05/23	CI
Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	15/09/22	CI
Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	21/03/22	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	20/03/22	CI
Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2021	29/09/21	CI
Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	26/04/21	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	25/04/21	CI
Zentiva Reinforces Its Presence in Greece by Signing A Partnership with the Company Lavipharm S.A	19/10/20	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	07/05/20	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	24/04/19	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	26/04/18	CI
Lavipharm Announces Consolidated Earnings Results for the First Half of 2015	21/09/15	CI
Robertet SA and Codif Recherche & Nature acquired Hitex S.A. from Lavipharm S.A. for €3.1 million.	01/01/14	CI
Lavipharm S.A. Announces Earnings Results for the Year Ended December 31, 2011	25/09/12	CI
Lavipharm S.A. Reports Consolidated and Parent Earnings Results for the Second Quarter and Six Months Ended June 30, 2012	29/08/12	CI
Lavipharm SA Reports Consolidated and Company Earnings Results for the First Quarter Ended March 31, 2012	29/05/12	CI

Chart Lavipharm S.A.

Duration

Period

More charts

Company Profile

Lavipharm SA is a Greek commercial and industrial enterprise engaged in the development, manufacture, marketing and distribution of pharmaceutical, cosmetic and over-the-counter (OTC) products. Its main pharmaceutical products cover such categories as anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological and gastrointestinal therapies. Its cosmetic products are offered under the brand names of Castalia Soins Dermocosmetiques and Laviderm Active Technology and are used for skin, face and body care, as well as for scalp and hair problems. Its OTC products include cold and flu remedies, oral care, dermatological products, condoms, antiseptics, analgesics, laxatives and gynecology products. It is the parent company of Lavipharm Group of Companies. In January 2014, Robertet SA acquired together with CODIF the HITEX company, specialized in subcontracting of carbon dioxide extraction, from Lavipharm SA.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
LAVIPHARM S.A.	+15.58%	167M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+15.37%	41.97B
OTSUKA HOLDINGS CO., LTD.	+22.56%	22.34B
SANDOZ GROUP AG	+14.89%	15.25B
CIPLA LIMITED	+16.53%	14B
ZYDUS LIFESCIENCES LIMITED	+49.78%	12.06B
ONO PHARMACEUTICAL CO., LTD.	-10.77%	6.8B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.18%	5.49B

Generic Pharmaceuticals

Lavipharm S.A.

Equities

LAVI

GRS246003008

Pharmaceuticals

Lavipharm S A : Announcement 1668/2023

Latest news about Lavipharm S.A.

Chart Lavipharm S.A.

Company Profile

Income Statement Evolution

Sector Generic Pharmaceuticals